Slides on Key Decisions in HIV Care: Optimizing Switch Strategies for Patients With Viral Suppression

Learn key considerations when selecting a new ART regimen for patients with viral suppression who need a change in HIV treatment. Topics include weighing the pros and cons of switching to contemporary 3-drug therapy regimens, oral 2-drug options, and long-acting injectable 2-drug regimens.
Daniel R. Kuritzkes, MD
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 908 KB
Released: June 7, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Interim results from the Phase II CALIBRATE study of lenacapavir in treatment-naive PLWH, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 24, 2021

REACH study: adherence to dapivirine vaginal ring and oral PrEP among African females 16-21 years, in Clinical Care Options (CCO) report from IAS 2021

Released: July 24, 2021

Post-hoc analysis of TANGO assessed changes in quantitative and qualitative viral load through Week 96 and inflammatory biomarkers from baseline to Week 96, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 22, 2021

IAS 2021 report from Clinical Care Options (CCO): CUSTOMIZE study shows that HCPs think monthly injectable CAB + RTV LA is feasible and acceptable despite COVID-19 disruptions

Released: July 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue